Mary V. Relling
University Of Tennessee System
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mary V. Relling.
Journal of Clinical Oncology | 2004
Mary V. Relling; Wenjian Yang; Soma Das; Edwin H. Cook; Gary L. Rosner; Michael D. Neel; Scott C. Howard; Raul C. Ribeiro; John T. Sandlund; Ching Hon Pui; Sue C. Kaste
PURPOSEnOne of the adverse effects of therapy for acute lymphoblastic leukemia (ALL) is osteonecrosis of the hip. Putative risk factors for osteonecrosis have included being female, white race, and older age. Our goal was to define possible genetic risk factors for osteonecrosis among children treated for newly diagnosed ALL.nnnMETHODSnUsing a candidate gene approach, we determined the genotypes for 16 common polymorphisms in genes likely to affect the pharmacokinetics or pharmacodynamics of antileukemic medications in 64 children with ALL. Therapy included glucocorticoids and antifolates. Magnetic resonance imaging of both hips was used to diagnose osteonecrosis, and was performed at similar times from the start of ALL therapy (P =.61) in the 25 patients with and the 39 patients without osteonecrosis (median, 447 days and 443 days, respectively).nnnRESULTSnIn addition to age older than 10 years (odds ratio [OR], 24.2; P =.0001) and white race (OR, 11.1; P =.037), host factors for osteonecrosis included the vitamin D receptor FokI start site CC genotype (OR, 4.5; P =.045), and the thymidylate synthase low activity 2/2 enhancer repeat genotype (OR, 7.4; P =.049).nnnCONCLUSIONnBecause folate-related and vitamin D-receptor genetic variants have been associated with bone and vasculature morbidity, these pharmacogenetic associations likely reflect the interaction of antileukemic medications with germline sensitivity to drug actions, and might identify ALL patients at highest risk to develop osteonecrosis.
Archive | 2006
William E. Evans; Mary V. Relling; Qing Cheng
Archive | 2006
Shinji Kishi; William E. Evans; Mary V. Relling
Archive | 2012
William L. Carroll; Stephen P. Hunger; Elizabeth A. Raetz; Richard Saffery; Mary V. Relling; Deepa Bhojwani; Laura E. Hogan; Julia Meyer; Jun J. Yang; Jinhua Wang; Nicholas C. Wong; Wenjian Yang
Archive | 2010
Mary V. Relling; Paul L. Martin; Paul Bowman; James S. Elliott; Cheryl L. Willman; Edwin H. Cook; Stella M. Davies; Michael J. Borowitz; Gary L. Rosner; Kristin Ritz; Meenakshi Devidas
Archive | 2008
Jun J. Yang; Deepa Bhojwani; Wenjian Yang; Xiangjun Cai; Gabriele Stocco; Kristine R. Crews; Jinhua Wang; Meenakshi Devidas; Stephen P. Hunger; Cheryl L. Willman; Elizabeth A. Raetz; Ching-Hon Pui; William E. Evans; Mary V. Relling; William L. Carroll
Journal of Clinical Oncology | 2005
Nobuko Hijiya; Melissa M. Hudson; Shelly Lensing; Gaston K. Rivera; Bassem I. Razzouk; R. C. Ribeiro; Jeffrey E. Rubnitz; Sandlund Jt; Mary V. Relling; Ching Hon Pui
Archive | 2003
Shinji Kishi; James Griener; Cheng Cheng; Soma Das; Edwin H. Cook; Deqing Pei; Melissa M. Hudson; Jeffrey E. Rubnitz; John T. Sandlund; Ching-Hon Pui; Mary V. Relling
Archive | 2003
Mathew J. Edick; Amar Gajjar; Hazem Mahmoud; Patricia L. Harrison; John C. Panetta; Gaston K. Rivera; Raul C. Ribeiro; John T. Sandlund; James M. Boyett; Ching-Hon Pui; Mary V. Relling
Archive | 2001
Ching-Hon Pui; Hazem Mahmoud; Joseph M. Wiley; Gerald M. Woods; Guy Leverger; Bruce M. Camitta; Caroline A. Hastings; Susan M. Blaney; Mary V. Relling; Gregory H. Reaman